Publications & Presentations

11.03.23 || CAT-248 (Engineered NK cells expressing CD70 CAR, IL15, and TGFβ DNR) demonstrates in vivo expansion, tumor infiltration, and durable regression of multiple CD70-expressing xenograft tumors

05.17.23 || Spinner flask modelling of wave-style bioreactors enables suspension-phase cell culture process development of allogeneic CAR-NK cell therapies

04.17.23 || CAT-248, an Allogeneic CD70-Directed CAR-NK Cell Therapy, Effectively Controls CD70-Positive Tumor Xenografts

04.17.23 || CAT-179, an allogeneic NK cell product expressing HER2-CAR, IL-15 and TGFβ dominant negative receptor, durably regresses HER2-expressing xenograft tumors in mic

03.28.23 || Selection of Engineered K562 Feeder Cell Clone for CAR-NK Drug Product Manufacturing Process

11.10.22 || Allogeneic natural killer cells engineered to express HER2-directed CAR, Interleukin 15, and TGF-beta dominant negative receptor effectively control HER2+tumors

11.10.22 || Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies

05.16.22 || A Synthetic Biology Approach to Address the Immunosuppressive Tumor Microenvironment: Novel TGF-β Switch Receptors Convert Inhibitory Signals into Enhanced NK Cell Activity

05.16.22 || Engineered Allogeneic Car-Natural Killer Cells Resist Tumor Microenvironment Immuno-Suppression by Expression of a TGFBR2 Dominant Negative Receptor

04.08.22 || Allogeneic Natural Killer Cells Engineered to Express HER2 CAR, Interleukin 15, and TGF-Beta Dominant Negative Receptor Effectively Control HER2+ Tumors

12.11.21 || Engineering CD70-Directed CAR-NK Cells for the Treatment of Hematological and Solid Malignancies

10.06.21 || Cryopreservation of Natural Killer and anti-CD19 Chimeric Antigen Receptor Natural Killer Cells